Danish Trial of Beta Blocker Treatment After Myocardial Infarction Without Reduced Ejection Fraction

  • End date
    Dec 17, 2022
  • participants needed
  • sponsor
    Bispebjerg Hospital
Updated on 23 January 2021
ejection fraction
heart failure
angina pectoris
unstable angina
beta blockers
beta blocker
acute myocardial infarction


To determine whether long-term treatment with oral betablocker (BB) therapy after myocardial infarction (MI) in patient with no heart failure reduces the composite outcome of death from any cause, recurrent MI, unstable angina pectoris, stroke or heart failure.


Aim: To determine whether long-term treatment with oral betablocker (BB) therapy after myocardial infarction (MI) in patient with no heart failure reduces the composite outcome of death from any cause, recurrent MI, unstable angina pectoris, stroke or heart failure.

Intervention: BB therapy versus no therapy.

Main Inclusion Criteria: Patient that have suffered a MI, both Non-ST elevation MI and ST elevation MI and can be randomized within 14 days of MI with no signs of heart failure and a left ventricular ejection fraction>40%.

Main Exclusion Criteria: Any indication or contraindication for BB treatment other than secondary prevention according to the treating cardiologist

Primary study endpoint: The composite of all-cause mortality, recurrent non-fatal MI, unstable angina pectoris, stroke or heart failure

Sample Size: A total of 3570 patients will be recruited and randomized 1:1 to BB treatment (type and dosage according to treating physician) or no BB treatment. Treatment must be initiated within 14 days of MI.

Location: All departments of cardiology in Denmark are invited to participate. All patients admitted to hospital for MI will be screened for in- and exclusion criteria and contacted if eligible.

Treatment Duration: Estimated (non) treatment duration of 2-4 years. Follow-up: Patients will be followed from the randomization date until end of follow-up with respect to the primary and most secondary endpoints.

Assessment of primary study and safety end points: Serious adverse events (SAE) will be monitored through patient reported hospital admission by surveys every 3 months combined with local follow-up on patients that do not respond to surveys

Intervention and dosage of BB treatment: The intervention will be active treatment with BB, type and dosage according to treating cardiologist choice and control will be standard care (without BB treatment). The treating cardiologist is recommended to use the highest dose deemed tolerable for the patient at the time of randomization. Dosage, adherence and cross-over will be monitored through linkage to the Danish Register of Medical Product Statistics.

Sample size considerations: Assuming a hazard ratio of 1.2 for the non-treated group compared to the treated the DANBLOCK trial has 80% power to detect this effect with an accumulation of 900 events of the primary endpoint. With 3570 patients randomized the investigators expect to reach 900 events within the study period.

Statistical Analysis: Intention-to-treat analysis will be carried out. Additionally, a secondary per-protocol analysis will be performed, where compliant BB-users patients are considered exposed during follow-up. Outcome analysis will be assessed by using cumulative incidence and Cox-regressions.

Data Safety Monitoring Board (DSMB): This committee consisting of two senior cardiologists and one trial-science statistician will overview safety and will have access to unblinded data. They will formally review the accumulating data every 6 months throughout the study period to ensure there is no avoidable increased harm to patients. The DSMB may recommend trial termination due to excess risk associated with no treatment with BB.

Recruitment: All patients admitted to hospital for MI will be screened for in- and exclusion criteria and contacted if eligible. Logistics of identifying and contacting the patients will be organized locally; some hospitals will randomize patients before discharge, others will contact patients after discharge. Patients will be randomized 1:1.

Publication policy: On study completion the results will be submitted for publication in an international medical journal. The results of this study will also be submitted to the Competent Authority and the Ethics Committee according to EU and Danish regulations.

Condition Myocardial Infarction, Heart Attack (Myocardial Infarction), STEMI, Acute Myocardial Infarction, Non-ST-elevation Myocardial Infarction, ST Elevation Myocardial Infarction
Treatment Carvedilol, Nebivolol, Bisoprolol, Metoprolol Succinate
Clinical Study IdentifierNCT03778554
SponsorBispebjerg Hospital
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have any of these conditions: ST Elevation Myocardial Infarction or Heart Attack (Myocardial Infarction) or Acute Myocardial Infarction or Myocardial Infarction?
Do you have any of these conditions: STEMI or Acute Myocardial Infarction or Myocardial Infarction or Heart Attack (Myocardial Infarction) or Non-ST-elevation Myocardial Infarction or ST ...?
Left ventricular ejection fraction > 40%
Myocardial infarction (MI) within previous two weeks
The diagnosis of acute MI must meet the Universal European Society of
Cardiology (ESC) definition of MI

Exclusion Criteria

Clinical evidence of heart failure at the time of discharge
Pregnancy or of child bearing age not using safe anticonception throughout the study period
Lack of signed informed consent and expected cooperation during follow-up
Any medical condition where beta blocker treatment is indicated according to the treating physician
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note